

NewsRelease

For Immediate Release:

Cadwalader Advises HealthCare Royalty Partners in \$150 Million Royalty Agreement with Karyopharm Therapeutics

New York, October 15, 2019 — Cadwalader advised HealthCare Royalty Partners in connection with a revenue interest financing transaction with Karyopharm Therapeutics for up to \$150 million to support the ongoing development and commercialization of XPOVIOTM (selinexor), Karyopharm's oral SINE compound that is currently marketed in the United States for the treatment of patients with heavily pretreated multiple myeloma.

The Cadwalader team was led by partner Ira Schacter and included Joo Kim, Steve Lenkowsky and Solomon Brown.

About Cadwalader, Wickersham & Taft LLP

Cadwalader, established in 1792, serves a diverse client base, including many of the world's leading financial institutions, funds and corporations. With offices in New York, London, Charlotte, Washington and Brussels, Cadwalader offers legal representation in antitrust, banking, capital markets, corporate finance, corporate governance, executive compensation, financial restructuring, intellectual property, litigation, mergers and acquisitions, private equity, private wealth, real estate, regulation, securitization, structured finance, tax and white collar defense. For more information, visit www.cadwalader.com.